PFG Advisors’s Charles River Laboratories CRL Stock Holding History

PFG Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$538K	Buy	2,371 +13	+0.6%	+$2.31K	0.03%	512
2026 Q1	$407K	Sell	2,358 -11	-0.5%	-$2.04K	0.02%	589
2025 Q4	$473K	Buy	+2,369	New	+$430K	0.02%	542
2022 Q4	–	Sell	-1,055	Closed	-$208K	–	570
2022 Q3	$208K	Sell	1,055 -55	-5%	-$11.9K	0.02%	485
2022 Q2	$238K	Sell	1,110 -70	-6%	-$17.1K	0.03%	340
2022 Q1	$335K	Sell	1,180 -2,030	-63%	-$626K	0.03%	325
2021 Q4	$1.21M	Buy	+3,210	New	+$1.25M	0.12%	215

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

PFG Advisors's CRL Position: Q2 2026 in Review

PFG Advisors increased its Charles River Laboratories (CRL) stake by 0.55% in Q2 2026, buying an estimated $2.31K and bringing the position to 2,371 shares worth $538K. The position accounts for 0.03% of the portfolio, ranked #512.

PFG Advisors first reported a position in CRL in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.21M in Q4 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

PFG Advisors held 2,371 shares of Charles River Laboratories worth $538K as of Q2 2026.
PFG Advisors bought 13 Charles River Laboratories shares in Q2 2026, an estimated $2.31K.
Charles River Laboratories made up 0.03% of PFG Advisors's portfolio in Q2 2026, its #512 holding.
PFG Advisors first reported a position in Charles River Laboratories in Q4 2021 and has held it in 7 quarters since.
PFG Advisors's Charles River Laboratories position peaked at $1.21M in Q4 2021.
565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on PFG Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.